{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:42Z","timestamp":1791925602191,"version":"4.3.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2023,3]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n This renal biopsy study documents clinical renal dysfunction and pathologic lesions encountered in patients after anti-TNF\n \u03b1<\/jats:italic>\n therapy and compares them with similar patients without treatment.\n <\/jats:p>\n <\/jats:list-item>\n \n \n This study highlights the spectrum of autoimmune, serologic, and other kidney adverse effects of anti-TNF\n \u03b1<\/jats:italic>\n therapy.\n <\/jats:p>\n <\/jats:list-item>\n \n Unrelated active or chronic renal lesions including amyloidosis secondary to the underlying systemic inflammatory states may be observed.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Anti-TNF\n \u03b1<\/jats:italic>\n inhibitors, as biological agents, are used in autoimmune inflammatory states, rheumatoid arthritis (RA), psoriatic arthritis (PA), and Crohn disease. They can induce autoimmune serologic responses and clinical disorders, including systemic vasculitis and lupus-like diseases, affecting the kidney.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Retrospective analysis of clinicopathologic features of kidney disease after anti-TNF\n \u03b1<\/jats:italic>\n therapy (treatment group) from our renal biopsy files from 2000 to 2018 is conducted and compared with 106 patients without therapy (control group).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty-eight patients using anti-TNF\n \u03b1<\/jats:italic>\n agents had renal biopsies: RA in 30, PA six, Crohn disease six, RA and PA one, RA and Crohn disease one, and others four. Twenty received etanercept, 15 adalimumab, eight infliximab, and five two forms of agents manifesting new-onset nephritic syndrome or CKD, 17 with AKI and 16 nephrotic syndrome, with recent ANCA and\/or lupus serology. The renal lesions were crescentic GN in eight, pauci-immune\u2013type in five, and ANCA+ in five. Lupus or lupus-like nephritis was seen in six: International Society of Nephrology\/Renal Pathology Society 2018 class II\u20142, class V\u20142, class III+V\u20141, and class IV+V\u20141, and concurrent fibrillary GN, scleroderma\/thrombotic microangiopathy (TMA), and amyloidosis in three. Renal lesions unrelated to anti-TNF\n \u03b1<\/jats:italic>\n therapy or underlying autoimmune disease were noted in 23 patients (\n e.g.<\/jats:italic>\n , diabetic nephropathy, interstitial nephritis, acute tubular injury, infection-related GN); immunoglobulin A nephropathy, renal sarcoidosis, and amyloid A amyloidosis were noted in five patients. TMA was recognized in five patients, one associated with scleroderma and one anti-phospholipid antibodies, and two had nephrotic syndrome secondary to podocytopathy. The control group was similar with higher number of immune-mediated GN, interstitial nephritis, and amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n The renal lesions during anti-TNF\n \u03b1<\/jats:italic>\n therapy have an autoimmune basis such as ANCA and lupus or lupus-like disease, correlated with new-onset serology, while others were similar to those observed in the control group. Renal biopsy findings integrated with clinical features and therapy can identify the underlying pathophysiologic process for appropriate management.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000000000000063","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T17:26:10Z","timestamp":1674840370000},"page":"363-373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Clinicopathologic Spectrum of Renal Lesions Following Anti-TNF-\u03b1 Inhibitor Therapy: A Single Center Experience"],"prefix":"10.34067","volume":"4","author":[{"given":"Joichi","family":"Usui","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York"},{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"12","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2165\/00003495-200464120-00001","article-title":"Biological agents for rheumatoid arthritis: targeting both physical function and structural damage","volume":"64","author":"Klinkhoff","year":"2004","journal-title":"Drugs."},{"issue":"5","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","article-title":"Safety of tumour necrosis factor-alpha antagonists","volume":"27","author":"Khanna","year":"2004","journal-title":"Drug Saf."},{"issue":"1","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol."},{"issue":"3","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00002281-200305000-00014","article-title":"Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis","volume":"15","author":"Ziolkowska","year":"2003","journal-title":"Curr Opin Rheumatol."},{"issue":"7","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.1780380213","article-title":"Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis","volume":"38","author":"Helin","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"10","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"issue":"19","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA."},{"issue":"4","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells."},{"issue":"9306","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(02)07718-8","article-title":"Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis","volume":"359","author":"Day","year":"2002","journal-title":"Lancet."},{"issue":"22","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med."},{"issue":"6","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","article-title":"Vasculitis induced by tumor necrosis factor-targeted therapies","volume":"10","author":"Ramos-Casals","year":"2008","journal-title":"Curr Rheumatol Rep."},{"issue":"8","key":"B14-20250823","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","article-title":"Vasculitis associated with tumor necrosis factor-alpha inhibitors","volume":"87","author":"Sokumbi","year":"2012","journal-title":"Mayo Clinic Proc."},{"issue":"09","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5414\/CNP62234","article-title":"Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis","volume":"62","author":"Doulton","year":"2004","journal-title":"Clin Nephrol."},{"issue":"2","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-007-0712-0","article-title":"C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab","volume":"27","author":"Ashok","year":"2008","journal-title":"Clin Rheumatol."},{"issue":"3","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1053\/j.ajkd.2007.10.043","article-title":"ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy","volume":"51","author":"Simms","year":"2008","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.nephro.2009.03.005","article-title":"Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis","volume":"5","author":"Fournier","year":"2009","journal-title":"Nephrol Ther."},{"issue":"1","key":"B19-20250823","first-page":"91","article-title":"Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis","volume":"28","author":"Mene","year":"2010","journal-title":"Clin Exp Rheumatol."},{"issue":"6","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/s10165-010-0333-3","article-title":"Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis","volume":"20","author":"Kaneko","year":"2010","journal-title":"Mod Rheumatol."},{"issue":"6","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3109\/s10165-010-0339-x","article-title":"Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-\u03b1","volume":"20","author":"Hirohama","year":"2010","journal-title":"Mod Rheumatol."},{"key":"B22-20250823","doi-asserted-by":"crossref","first-page":"80","DOI":"10.12659\/AJCR.883841","article-title":"Appearance of ANCA - associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment","volume":"14","author":"Reitblat","year":"2013","journal-title":"Am J Case Rep."},{"issue":"11","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/1756-185X.12612","article-title":"ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha","volume":"20","author":"Alkhunaizi","year":"2017","journal-title":"Int J Rheum Dis."},{"issue":"4","key":"B24-20250823","first-page":"740","article-title":"Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept","volume":"32","author":"Mor","year":"2005","journal-title":"J Rheumatol."},{"issue":"4","key":"B25-20250823","first-page":"221","article-title":"Clinical and histological features of lupus nephritis induced by anti-TNF therapy","volume":"1","author":"Piccolo","year":"2008","journal-title":"NDT Plus."},{"issue":"7","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.01010115","article-title":"Drug-induced glomerular disease: attention required","volume":"10","author":"Radhakrishnan","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:00:53Z","timestamp":1786478453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000000000063","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}